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Abstract 
Objectives: We sought to systematically evaluate the external validity of a contemporary randomized controlled 
stent trial (BIOSCIENCE). 
Methods: Baseline characteristics and clinical outcomes of patients enrolled into the BIOSCIENCE trial at Bern 
University Hospital (n= 1,216) were compared to those of patients included in the CARDIOBASE Bern PCI Registry 
at the same institution (n= 1,045). The primary study endpoint was the rate of target lesion failure (TLF), defined as a 
composite of cardiac death, target vessel-myocardial infarction (MI) or target lesion revascularization (TLR), at 1 
year. 
Results: Women were underrepresented in the RCT compared to the registry (25% vs. 29.4%, p= 0.020). Non-
participants were older compared to study participants (69.2 ± 12.4 vs. 67.0 ± 11.6, p<0.001), and had a higher 
prevalence of previous cerebrovascular events (10.8% vs. 5.2%, p<0.001), and chronic renal failure (35.5% vs. 
15.6%, p<0.001).  ST-segment elevation myocardial infarction (STEMI) and Killip class IV at presentation were 
more common among non-participants than participants (30.7% vs. 21.1%, p<0.001 and 7.8% vs. 0.4%, p<0.001, 
respectively). At 1-year, non-participants experienced a significantly higher rate of TLF, (15.0% vs. 6.5%, p<0.001), 
and patient-oriented composite endpoint (POCE), including death, MI or any repeat revascularization (21.6% vs. 
11.2%, p<0.001). There was a significant interaction between POCE and presence or absence of an acute coronary 
syndrome in participants versus non-participants, respectively (p= 0.009). 
Conclusions: Non-participants of this all-comers trial had a higher risk profile and adverse prognosis compared to 
study participants. Further efforts are needed to improve the external validity of contemporary RCTs. 
 
Key words: generalizability, interventional trial, drug-eluting stents. 
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Introduction 
Drug-eluting stents (DES) represent the standard of care for percutaneous coronary revascularization[1] and 
transformed the field of interventional cardiology conferring higher efficacy as compared to bare metal stents 
(BMS).[2-4] Moreover, new generation DES featuring reduced strut thickness, ameliorated design, biocompatible 
polymers and reduced dosages of anti-proliferative drugs surpassed first generation DES in terms of efficacy and 
safety.[5]  
Randomized controlled trials (RCTs) are the cornerstone of treatment recommendations and clinical guidelines. 
During the past decade, the evolution of stent technology was paralleled by the refinement of design and accuracy of 
randomized trials assessing their performance. Ensuring internal validity of RCTs by reducing the risk of chance, 
confounding and potential bias has been strongly recommended and adopted by a growing number of researchers.[6] 
The need to provide generalizable evidence prompted the design of trials with minimal exclusion criteria, generally 
referred to as all-comer design.[7,8] However, the adequacy of contemporary interventional trials to reflect routine 
clinical practice outside of study protocols needs to be delineated. Indeed, inadequate consideration of issues 
affecting the external validity is one of the most common criticisms of RCTs.[9]  
The BIOSCIENCE trial was a randomized controlled multicenter study showing non-inferiority of the biodegradable 
polymer sirolimus-eluting Orsiro stent (BP-SES) to the durable polymer everolimus-eluting Xience stent (DP-EES) 
in a population with minimal exclusion criteria.[10] The objective of the present analysis was to compare clinical 
features and outcomes of study participants at Bern University Hospital versus subjects undergoing percutaneous 
coronary intervention (PCI) at the same institution but not included in the trial.  
 
Methods 
 
Study population 
 
The study population included participants of the BIOSCIENCE trial (NCT01443104) that were enrolled at the Bern 
university Hospital and non-participants included in the CARDIOBASE Bern PCI registry during the same study 
period (between February 2012 and May 2013). 
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The BIOSCIENCE was an investigator-initiated, multicenter, single-blind, randomized trial assessing the non-
inferiority of  the Orsiro BP-SES (Biotronik AG, Bülach, Switzerland) relative to the Xience DP-EES (Abbott 
Vascular, Abbott Park, IL, USA).[11] 
 Eligibility was defined by: age above 18 years, presence of stable coronary artery disease (CAD) or acute coronary 
syndromes (ACS), de-novo or restenotic lesions in native coronary arteries or bypass grafts. Patients were excluded 
in case of pregnancy, inability to provide consent, participation in another trial, intolerance to aspirin, clopidogrel, or 
components of DES, and surgery planned within 6 months after the index PCI that would require discontinuation of 
dual antiplatelet therapy (DAPT).[10] The CARDIOBASE Bern PCI Registry  (NCT02241291) collects clinical, 
procedural and outcome data of patients undergoing PCI in the setting of stable CAD or ACS at Bern University 
Hospital. For the purpose of the present analysis, patients included in the registry during the enrollment time of the 
BIOSCIENCE trial were used.  The trial and the registry were managed in accordance with the Declaration of 
Helsinki and patients provided written informed consent. 
 
Procedures and follow-up 
Participants of the BIOSCIENCE trial were randomly allocated in a 1:1 ratio to the treatment with BP-SES or DP-
EES, respectively. Details of the study devices have previously been reported.[10] Clinical follow-up was performed 
at 30 days and 1 year after PCI. Regardless of patient allocation, PCI was performed according to international 
recommendations.[1] As for study protocol, all patients in the trial received new generation DES (BP-SES or DP-
EES). Non-participants also received new generation DES in the vast majority of cases, including zotarolimus-
eluting stents (Resolute, Medtronic Cardiovascular), biodegradable polymer DES (BioMatrix, Biosensors Europe;  
Synergy, Boston Scientific Corporation), and bioresorbable vascular scaffold (Absorb, Abbott Vascular). The 
Clinical Trials Unit and the Department of Cardiology at Bern University Hospital, had the responsibility of data 
monitoring and storing for both the trial and the registry. Adverse events were adjudicated by a dedicated clinical 
events committee in both study participants and non-participants, respectively.   
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Study endpoints 
The primary endpoint of this study was the rate of target lesion failure (TLF), defined as a composite of cardiac 
death, target vessel-myocardial infarction (MI) or target lesion revascularization (TLR), at 1 year.  Secondary 
endpoints were a patient-oriented composite endpoint (POCE), including all-cause death, MI or any repeat 
revascularization; all cause death; cardiac death; MI; repeat revascularization; and definite or probable stent 
thrombosis (ST). Definitions of study endpoints have been reported in detail elsewhere.[10] Briefly, cardiac death 
was considered as any death of immediate cardiac cause, death related to the procedure, unwitnessed death, and 
death of unknown cause. Myocardial infarction was defined as Q wave and non–Q wave according to the 
electrocardiographic criteria of the Minnesota code manual.[12] The definition of MI included: spontaneous MI, 
peri-procedural MI and reinfarction. TLR was considered as any repeat percutaneous or surgical intervention because 
of a stenosis within the stent or within the 5-mm borders proximal or distal to the stent. ST was defined on the basis 
of the Academic Research Consortium criteria.[13] 
 
Statistical analysis 
Continuous variables were expressed as mean ± standard deviations (SD, groups compared with t-tests); categorical 
variables were summarized as frequencies (%, groups compared with Fisher’s or chi-square tests). P-values derived 
from General or Generalized Linear Mixed Models for the per-lesion analyses, accounting for lesions nested within 
patients. A Mantel-Cox method was used to compare the outcomes between participants and non-participants.  
In case of zero events in any comparator group, we reported continuity corrected risk ratios with p-values from 
Fisher’s exact tests. Risk ratio (RR) with their 95% confidence intervals (CI) were provided. P-values for interactions 
were obtained with approximate χ2 tests for unequal RRs in the subgroups. Survival curves up to one-year follow-up 
were constructed for time-to-event variables with Kaplan-Meier estimates and compared by the log-rank test. A 
landmark analysis with a landmark set at 30 days to provide insights into the differences in early and late event rates 
through the different study cohorts was also performed. Stratified analyses were pre-defined: Acute Coronary 
Syndrome, ST-elevation Myocardial Infarction, Diabetes, Gender, Age ≥65 years, BMI ≥30 kg/m2, Renal failure, 
Multivessel treatment, In-stent restenosis (any lesion), Long lesions (total stent length in any lesion >20mm), Small 
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vessels (stent diameter in any lesion <3.0mm), Stent used (BP-SES only vs DP-EES only). We also re-analyzed the 
primary endpoint after excluding cardiogenic shock patients. A p value of <0.05 was considered significant, and all 
tests were 2-tailed. All analyses were carried out with Stata 14 (College Station, TX: StataCorp LP). 
 
Results 
Study population 
Between February 2012 and May 2013, 2,261 patients underwent PCI in our institution. 1,216 patients participated 
in the BIOSCIENCE trial (57,3% of the overall trial population); the remaining 1,045 patients not participating in the 
trial were included into the CARDIOBASE Bern PCI Registry (Figure 1). 
 
Baseline clinical characteristics 
Table 1 shows baseline clinical characteristics of participants in the BIOSCIENCE trial as compared to non-
participants. Women were underrepresented in the RCT compared to the registry (25% vs. 29.4%, p= 0.020). 
Patients included into the registry were older (69.2 ± 12.4 years vs. 67.0 ± 11.6 years, p<0.001), and had a 
significantly higher prevalence of previous cerebrovascular events (10.8% vs. 5.2%, p<0.001), and chronic renal 
failure (35.5% vs. 15.6%, p<0.001). 
 
 Moreover, non-participants presented with lower left ventricular ejection fraction (51.2 ± 15.5% vs. 54.6 ± 12.3%, 
p<0.001).  
Conversely, a family history of CAD (25.9% vs. 18.0%, p<0.001) and previous PCI (30.2% vs. 22.1%, p<0.001) 
were more common among study participants.  
Regarding clinical presentation, the registry included a significantly higher number of patients with ST-segment 
elevation myocardial infarction (STEMI) (30.7% vs. 21.1%, p<0.001) and patients with Killip class IV at 
presentation (7.8% vs. 0.4%) compared with patients included into the RCT. Study arms also differed with respect to 
medical treatment at baseline: patients in the trial were more likely to be on DAPT (20.1% vs. registry 9.9%, 
p<0.001), statins (54.3% vs. 46.3%, p<0.001) and beta-blockers (48.6% vs. 42.0%, p= 0.003). In contrast, oral 
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anticoagulation (OAC) was more frequent among patients in the registry (8.4% vs. 12.9%, p= 0.001). Similarly, at 
discharge, 98.1% versus 92.4% of patients  were on DAPT in the trial and registry, respectively (p<0.001);  higher 
use of ticagrelor and statins was reported among patients included in the trial. (Online Resource 1) 
 
Procedural characteristics 
Angiographic and procedural characteristics are summarized in Online Resource 2. There were no significant 
differences in the number of treated lesions and target-vessel location between the two cohorts. In addition, the 
number of complex lesions was comparable between study participants and non-participants. As per study protocol, 
participants of the trial received BP-SES or DP-EES, and only 3 patients received bare-metal stents (BMS). The vast 
majority of subjects included in the registry were treated with DES, and only 5.9% received BMS. Significantly 
higher use of intra-aortic balloon pump counterpulsation (2.9% vs. 0.3%) and vasopressors (8.0% vs. 0.9%) was 
reported in the registry  compared to the RCT. 
 
Clinical outcomes   
Table 2 and Figure 2 show clinical outcomes of participants relative to non-participants after 1 year from the index 
procedure.  
The rate of the primary endpoint, TLF, amounted to 6.5% in the RCT versus 15.0% in the registry, respectively (RR 
0.40, 95% CI 0.30-0.53, p<0.001).  
The patient-oriented composite endpoint (POCE) occurred in 11.2% of RCT compared to 21.6% of registry patients 
(RR 0.47, 95% CI 0.38-0.59, p<0.001).  
RCT participants experienced significantly lower rates of all cause-death (3.1% vs. 14.1%, RR 0.20, 95% CI 0.14-
0.29, p<0.001), cardiac death (2.0% vs. 10.5%, RR 0.18, 95% CI 0.11-0.28, p<0.001), MI (4.0% vs. 5.8%, RR 0.66, 
95% CI 0.45-0.98, p= 0.038) and definite or probable ST (2.7% vs. 10.4%, RR 0.25, 95% CI 0.17-0.37, p<0.001) 
compared to registry participants. Rates of repeat revascularization (including target lesion and target vessel 
revascularization) were not significantly different between the two study cohorts (7.4% vs. 7.8%, RR 0.92, 95% CI 
0.67-1.27, p= 0.614). The rate of POCE was not affected by the type of stent used, in both the registry and the trial 
(Online Resource 3). 
In a landmark analysis of all-cause death, MI, repeat revascularization and POCE with the landmark set at 30 days, 
registry participants experienced significantly higher rates of adverse events compared to RCT participants within 
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the first month after PCI (Figure 3). The difference in outcome was preserved up to 1 year for the rate of all-cause 
death and POCE, whereas a reversal of the trend for repeat revascularizations, disfavoring patients in the registry, 
was observed beyond 30 days. Moreover, after the first month, rates of MI did not significantly differ between the 
two cohorts. 
Figure 4 shows the risk of POCE among RCT versus registry patients across pre-specified subgroups. The lower risk 
of POCE in RCT patients was particularly pronounced among patients presenting with ACS (RR 0.38, 95% CI 0.28-
0.51) compared to patients presenting with stable coronary artery disease (RR 0.70, 95% CI 0.49-0.99), with a 
statistically significant interaction for presence or absence of ACS (p= 0.009).  
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Discussion 
 
The present analysis comparing all-comer study RCT participants with registry participants with regards to clinical 
characteristics, presentation and outcome recruited during the same time period at a single tertiary care center 
provided the following findings: 
 
1. RCT participants were younger, more commonly male, and had a lower clinical risk profile as compared to 
registry participants; along the same line, patients presenting with STEMI and cardiogenic shock were 
underrepresented in the RCT. 
2. The risk of death, patient-oriented adverse events and ST was more than doubled in registry participants 
compared to RCT participants up to 1 year after PCI. While the effect on all-cause mortality was consistent 
within the first 30 days and beyond, the difference with regards to MI and repeat revascularization was limited 
to the first 30 days after intervention.  
3. The difference in the risk of POCE between RCT participants and registry participants was accentuated in 
patients presenting with ACS. 
RCTs are considered to generate the most reliable evidence, and provide the robust basis of treatment 
recommendations, expert consensus, and clinical guidelines. The use of new generation DES is currently 
recommended in all patient and lesion subsets among patients undergoing PCI, on the basis of head-to-head 
comparisons of different devices.[1,14-16] The development of novel stent designs bearing the potential to refine the 
performance of new generation DES and scaffolds is paralleled by a progressive evolution of trial designs. Sample 
size calculations are performed to reduce the risk of chance, and randomization and stratification are used to 
minimize the risk of confounding factors. At the same time, broad inclusion criteria are applied to minimize selection 
and entry bias, and study subjects and event adjudication committees are blinded to treatment in order to avoid 
information bias[6].  
Consistently, contemporary trials aim for the recruitment of large numbers of patients with minimal exclusion 
criteria to generate robust findings translatable into routine clinical practice.  
Overall, these features attest to the internal validity of RCTs but proved to be not sufficient to ensure the 
generalizability of their results.[17,18]  
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The systematic appraisal of external validity of relevant RCTs could help to identify factors still affecting their 
effectiveness in representing the real world outside of study protocols.   
Significant differences in baseline characteristics and outcomes, for instance, were described for RCT participants  
and non-participants of the LEADERS and RESOLUTE III trials, two large “all-comers” PCI trials.[19]   
Furthermore, marked differences with regard to hospital characteristics between participating and non-participating 
sites of the recent DAPT trial were reported; a lower cardiovascular disease burden and younger age were also 
described for participants as compared to non-participants in the trial.[20]  
Along the same line, we found that trial participants had a lower risk profile and higher probability of mid-term 
survival than non-participants. Even though the rationale for non-inclusion of individual subjects had not been 
prospectively recorded, the important differences in baseline characteristics suggests a tendency to systematically 
exclude patients with specific features. Female gender continued to be an important determinant of non- participation 
in the trial. Sex-specific aspects of clinical presentation of CAD and inadequate awareness of the burden of the 
disease prevent an adequate proportion of women to be enrolled in interventional trials.[21] This underrepresentation 
hampers our knowledge about the typical aspects of the disease in female compared with male patients and 
aggravates a gender gap. Several previous reports, indeed, described disparity in the provision of medical care in 
female population with cardiac diseases.[22-24]  
Advanced age, multiple comorbidities, need for long-term OAC and a more compromised status at presentation also 
increased the probability to be not included into the trial. These baseline differences translated into worse clinical 
outcomes of non-participants, especially in the early period after PCI.  
All-cause and cardiac death were the stronger determinants of higher risk of the composite endpoints whilst rates of  
ischemic events (MI and repeat revascularization) were not significantly different between groups.  
This finding has two main implications: 1) it reinforces the notion that critically ill patients, with pre-procedural 
higher probability to die, were preferentially not included into the trial; 2) the widespread use of new generation DES 
has the potential to mitigate the effects of higher baseline risk profiles on the risk of restenosis. 
Indeed, rates of repeat revascularization were higher among registry-participants during the early period after PCI 
(probably driven by higher occurrence of ST) but they were not different between the groups up to 1 year.   
As an additional finding, we observed that the imbalance in terms of risk of adverse events between RCT and 
registry participants was prominent in the setting of ACS. The tendency to enroll lower risk patients was mirrored by 
a higher proportion of subjects with STEMI and/or cardiogenic shock at time of presentation in the registry. In 
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emergency conditions, patients are less prone or unable to voluntarily accept the participation in studies. Inability to 
provide informed consent, indeed, was one of the main reasons for exclusion of subjects from two large “all-comers” 
trials and was reported mainly among patients with acute MI.[19]  However, other factors hindering the participation 
in the trials in case of acute MI are still largely unrecognized because of an inadequate use of screening logs. 
Overall, our results raise important concerns about the generalizability of current interventional trials: particularly, 
the persistent underrepresentation of higher risk patients limits our knowledge on how to optimize care among 
patients at highest risk.[25,15,26] A number of tools have been proposed to overcome this issue: simplified 
acquisition of informed consent to facilitate the enrollment of patients, especially in emergency situations;[19] use of 
dedicated checklists inspired to the CONSORT flow diagram;[9] 
 systematic collection of screening logs;[19] identification of a dedicated space within journals to report the 
information about external validity of published RCTs;[27] embedding of clinical trials in registries.[28] 
Their implementation in routine clinical practice could help to enhance the relevance of scientific research in several 
settings. 
Our study has the following limitations: 1) Although the BIOSCIENCE trial recruited patients at nine hospitals, the 
present analysis was limited to patients enrolled at a single institution. We acknowledge that considering the 
experience of a single site disregards the multicenter design of the trial; however, the ability to compare participants 
with patients included, during the same period, in a dedicated PCI registry with active follow-up and uniform 
adjudications of adverse events represents a major strength of our work; 2) We did not prospectively record reasons 
for non-inclusion into the BIOSCIENCE trial precluding an accurate estimate of actual reasons for non-inclusion; 3) 
Selection of registry participants is only one of the numerous categories of external validity; 4) This was a post hoc 
analysis open to all the limitations of such investigations. 
 
Conclusions 
Several factors still affect the generalizability of contemporary interventional RCTs. Our study shows important 
differences between study participants and non-participants with regards to baseline characteristics and clinical 
outcomes in an unselected patient population referred for PCI. Disparities were not accounted for by study exclusion 
criteria, and were particularly pronounced among patients presenting with ACS. Major efforts are needed to ensure 
adequate representativeness of real world patients and the consequent wide application of the study results. 
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Figures 
 
Figure 1.  Study flow diagram for comparison between participants in the BIOSCIENCE trial and non-participants 
entered in the CARDIOBASE Bern PCI Registry. 
BP-SES: Biodegradable polymer- sirolimus eluting stent ; DP-EES : Durable polymer-everolimus eluting stent 
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Figure 2. Kaplan-Meier graphs of All-cause Death (A), Myocardial infarction (B), any Repeat Revascularisation (C) 
and POCE (D) at 1-year follow-up.  
BIOSCIENCE= Blue line;  CARDIOBASE Bern PCI Registry = Red line. 
MI, Myocardial infarction; POCE, Patient oriented composite endpoint. 
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Figure 3. Landmark at 30 days analyses of All-cause Death (A), Myocardial infarction (B), any Repeat 
Revascularisation (C) and POCE (D) at 1-year follow-up. 
BIOSCIENCE= Blue line CARDIOBASE Bern PCI Registry = Red line. 
MI, Myocardial infarction; POCE, Patient oriented composite endpoint. 
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Figure 4. Stratified analyses of POCE at 1-year in pre-specified sub-groups. 
BMI, Body mass index; BP-SES: Biodegradable polymer- sirolimus eluting stent; CAD, Coronary artery disease; 
MI, Myocardial infarction; DP-EES: Durable polymer-everolimus eluting stent; POCE, Patient oriented composite 
endpoint. 
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Table 1. Baseline clinical characteristics of participants and non-participants of the BIOSCIENCE trial 
  RCT participants Registry participants Difference (95% CI) p-value 
  n= 1,216 n= 1,045     
          
Age- years (SD) 67.0 ± 11.6 69.2 ± 12.4 -2.3 (-3.3; -1.3) <0.001 
Male gender-  no. (%) 912 (75.0%) 738 (70.6%) -4.4%  (-8.0%;  -0.7%) 0.020 
Body mass index- kg/m2 27.7 ±  4.6 27.0 ±  5.0 0.6  (0.2;  1.0) 0.003 
Diabetes mellitus- no. (%) 276 (22.7%) 250 (24.1%) 1.4%  (-2.1%;   4.9%) 0.454 
Oral-treated 192 (15.8%) 149 (14.5%) -1.3%  (-4.3%;   1.7%) 0.409 
Insulin-treated 99  (8.1%) 102  (9.9%) 1.8%  (-0.6%;   4.2%) 0.159 
Hypertension- no. (%) 840 (69.2%) 715 (69.7%) 0.5%  (-3.3%;   4.3%) 0.818 
Hypercholesterolemia- no. (%) 811 (66.7%) 689 (67.3%) 0.5%  (-3.4%;   4.4%) 0.822 
Current smoker- no. (%) 339 (27.9%) 278 (27.8%) 0.1%  (-3.7%;   3.9%) 0.962 
Family history of CAD- no. (%) 313 (25.9%) 185 (18.0%) -7.9% (-11.3%;  -4.4%) <0.001 
Previous MI- no. (%) 238 (19.6%) 188 (18.2%) -1.4%  (-4.7%;   1.8%) 0.418 
Previous PCI- no. (%) 367 (30.2%) 228 (22.1%) -8.1% (-11.8%;  -4.5%) <0.001 
Previous CABG- no. (%) 136 (11.2%) 132 (12.8%) 1.6%  (-1.1%;   4.3%) 0.267 
Atrial fibrillation- no. (%) 125 (10.3%) 122 (11.9%) 1.6%  (-1.0%;   4.2%) 0.250 
Previous stroke or TIA- no. (%) 63  (5.2%) 112 (10.8%) 5.6%   (3.4%;   7.8%) <0.001 
Peripheral vascular disease- no. (%) 101  (8.3%) 111 (10.7%) 2.4%  (-0.0%;   4.8%) 0.051 
Renal Failure (GFR<60 ml/min)- no. (%) 178 (15.6%) 299 (35.5%) -19.9% (-23.6%; -16.2%) <0.001 
Clinical presentation     
Congestive heart failure- no. (%) n = 1209 n = 1045   <0.001 
Killip I 1037 (85.8%) 737 (70.5%) 15.2%  (11.9%;  18.6%)   
Killip II 144 (11.9%) 154 (14.7%) -2.8%  (-5.6%;  -0.0%)   
Killip III 23  (1.9%) 72  (6.9%) -5.0%  (-6.6%;  -3.3%)   
Killip IV 5  (0.4%) 82  (7.8%) -7.4%  (-9.0%;  -5.9%)   
Left ventricular ejection fraction- %  54.6 ± 12.3 51.2 ± 15.5 3.3  (2.1;  4.5) <0.001 
Acute coronary syndrome or Other indication- no. 
(%) n = 1216, n =  977,   <0.001 
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Unstable angina  74  (6.1%) 41  (4.2%) 1.9%   (0.0%;   3.8%) 0.054 
NSTEMI 307 (25.2%) 270 (27.6%) -2.4%  (-6.1%;   1.3%) 0.223 
STEMI 256 (21.1%) 300 (30.7%) -9.7% (-13.3%;  -6.0%) <0.001 
Stable angina- no. (%) 404 (33.2%) 283 (29.0%) 4.3%   (0.4%;   8.2%) 0.033 
Silent ischemia- no. (%) 175 (14.4%) 83  (8.5%) 5.9%   (3.2%;   8.6%) <0.001 
Baseline Medications- no. (%)         
Aspirin 711 (59.8%) 497 (53.4%) -6.4% (-10.7%;  -2.2%) 0.004 
Clopidogrel 176 (14.8%) 105 (11.3%) -3.5%  (-6.4%;  -0.6%) 0.020 
Prasugrel 44  (3.7%) 7  (0.8%) -3.0%  (-4.3%;  -1.6%) <0.001 
Ticagrelor 58  (4.9%) 17  (2.2%) -2.7%  (-4.4%;  -1.0%) 0.002 
Any dual antiplatelet treatment  239 (20.1%) 92  (9.9%) 10.2%   (7.1%;  13.3%) <0.001 
Oral anticoagulants - Vitamin K antagonists 100  (8.4%) 120 (12.9%) 4.5%   (1.9%;   7.1%) 0.001 
Novel oral anticoagulants  4  (0.3%) 1  (0.1%) -0.2%  (-0.7%;   0.2%) 0.654 
Any antithrombotic treatment 104  (8.8%) 121 (13.0%) -4.2%  (-6.9%;  -1.6%) 0.002 
Statins 644 (54.3%) 431 (46.3%) -8.0% (-12.2%;  -3.7%) <0.001 
ACE-inhibitors or receptor blockers 320 (27.0%) 246 (26.5%) -0.5%  (-4.3%;   3.3%) 0.843 
Betablockers 576 (48.6%) 390 (42.0%) -6.5% (-10.8%;  -2.3%) 0.003 
          
Data expressed as n (%) or means ± standard deviations. 
ACE, Angiotensin converting enzyme; CABG, Coronary artery bypass grafting; CAD, Coronary artery disease; GFR, Glomerular filtration rate; MI, Myocardial infarction; 
NSTEMI, Non ST-segment elevation myocardial infarction; PCI, Percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIA, Transient ischemic 
attack. 
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Table 2. 1-year clinical outcomes in participants and non-participants of the BIOSCIENCE trial 
  RCT participants Registry participants Risk difference  (95% CI) 
Risk Ratio  
(95% CI) p-value 
  n= 1,216 n= 1,045       
            
All-cause Death 37 (3.1) 136 (14.1) -9.97 (-12.23 to -7.71) 0.20 (0.14-0.29) <0.001 
Cardiac death 24 (2.0) 101 (10.5) -7.69 (-9.65 to -5.74) 0.18 (0.11-0.28) <0.001 
Myocardial Infarction (any) 47 (4.0) 54 (5.8) -1.30 (-3.03 to 0.42) 0.66 (0.45-0.98) 0.038 
Q-wave 10 (0.8) 8 (0.9) 0.06 (-0.68 to 0.79) 0.94 (0.37-2.38) 0.904 
Non Q-wave 38 (3.2) 47 (5.1) -1.37 (-2.96 to 0.22) 0.61 (0.40-0.94) 0.024 
Target Vessel Myocardial Infarction 31 (2.6) 32 (3.4) -0.51 (-1.88 to 0.86) 0.76 (0.46-1.25) 0.279 
Q-wave 8 (0.7) 3 (0.3) 0.37 (-0.19 to 0.93) 2.09 (0.55-7.92) 0.265 
Non Q-wave 23 (1.9) 29 (3.0) -0.88 (-2.14 to 0.37) 0.62 (0.36-1.08) 0.088 
Cardiac death or MI 69 (5.8) 147 (15.2) -8.39 (-10.87 to -5.92) 0.35 (0.26-0.47) <0.001 
Repeat revascularisation (any) 87 (7.4) 69 (7.8) 0.55 (-1.54 to 2.64) 0.92 (0.67-1.27) 0.614 
Percutaneous repeat revascularization  (any) 84 (7.1) 67 (7.5) 0.50 (-1.56 to 2.55) 0.91 (0.66-1.26) 0.586 
Surgical repeat revascularization (any) 6 (0.5) 5 (0.6) 0.01 (-0.56 to 0.59) 0.87 (0.27-2.81) 0.817 
  Any target lesion revascularization 38 (3.2) 37 (4.1) -0.42 (-1.90 to 1.07) 0.75 (0.48-1.19) 0.226 
Percutaneous TLR 35 (3.0) 36 (4.0) -0.57 (-2.02 to 0.88) 0.71 (0.44-1.14) 0.156 
Surgical TLR 4 (0.3) 2 (0.2) 0.14 (-0.28 to 0.55) 1.45 (0.27-7.69) 0.661 
Any target vessel revascularization 50 (4.2) 48 (5.4) -0.48 (-2.17 to 1.21) 0.76 (0.51-1.14) 0.180 
Any Percutaneous TVR 48 (4.1) 46 (5.1) -0.45 (-2.11 to 1.20) 0.76 (0.51-1.15) 0.190 
Any Surgical TVR 4 (0.3) 3 (0.4) 0.04 (-0.42 to 0.50) 0.97 (0.22-4.25) 0.969 
Cerebrovascular Event CVE 15 (1.3) 19 (2.1) -0.58 (-1.60 to 0.44) 0.58 (0.29-1.14) 0.111 
Strokea 12 (1.0) 17 (1.9) -0.64 (-1.59 to 0.31) 0.52 (0.24-1.09) 0.076 
Ischemic stroke 11 (0.9) 14 (1.6) -0.44 (-1.31 to 0.44) 0.58 (0.26-1.28) 0.170 
Transient ischemic attack 4 (0.3) 2 (0.2) 0.14 (-0.28 to 0.55) 1.48 (0.27-8.02) 0.650 
Cardiac death, TV-MI or TLRb 78 (6.5) 145 (15.0) -7.46 (-9.97 to -4.95) 0.40 (0.30-0.53) <0.001 
Death, MI, or any Repeat revascularizationc 134 (11.2) 209 (21.6) -8.98 (-11.98 to -5.98) 0.47 (0.38-0.59) <0.001 
Definite stent thrombosis  9 (0.8) 16 (1.7) -0.79 (-1.68 to 0.10) 0.43 (0.19-0.99) 0.041 
Definite or Probable stent thrombosis  33 (2.7) 102 (10.4) -7.05 (-9.06 to -5.03) 0.25 (0.17-0.37) <0.001 
            
Number of first events and percentages are reported. Rate ratios RR (95% CI) are estimated using the Mantel-Cox method with two-sided p-values from log-rank test 
[Bioscience/Registry]. All events were censored beyond 365 days. Continuity corrected RR with Fisher's exact test for zero outcomes.  
CVE, Cerebrovascular events ; MI, Myocardial infarction; TLR, Target lesion revascularisation; TV, Target vessel ; TVR, Target vessel revascularisation.  a Includes ischemic stroke, 
intracerebral hemorrhage and unclear etiology CVE.  b Target lesion failure (TLF) - Device oriented composite endpoint.  c Patient oriented composite endpoint(POCE). 
 
